Population Pharmacokinetics of Radotinib in Healthy Volunteers and Patients with Chronic Myeloid Leukemia

<b>Background/Objectives</b>: Radotinib is a second-generation tyrosine kinase inhibitor (TKI) that has been used for treatment of chronic myeloid leukemia (CML). This study was performed for the first time to characterize the pharmacokinetics of radotinib, identify the factors contributing to pharm...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Minseo Kang, Jiwon Kim, Yerin Lee, Jae Soo Shin, Min Soo Park, Qian Jiang, Eun Kyoung Chung, Jangik I. Lee
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-11-01
Edice:	Pharmaceuticals
Témata:	radotinib nonlinear mixed-effects modeling population pharmacokinetics tyrosine kinase inhibitor chronic myeloid leukemia
On-line přístup:	https://www.mdpi.com/1424-8247/18/11/1705
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!